Nuvo Pharmaceuticals Announces Health Canada Approves Suvexx For The Acute Treatment of Migraine
N
uvo Pharmaceuticals Inc. (Nuvo or the Company) (TSX: NRI; OTCQX: NRIFF), a Canadian focused healthcare company with global reach and a diversified portfolio of commercial products, today announced that its wholly owned subsidiary, Aralez Pharmaceuticals Canada Inc. (Aralez Canada) has received a Notice of Compliance from Health Canada for Suvexx.
Suvexx (sumatriptan succinate and naproxen sodium tablets) is a fixed-dose combination prescription medication, indicated for the acute treatment of migraine attacks with or without aura in adults. Aralez Canada anticipates launching Suvexx into the approximately $130 million Canadian prescription acute migraine market in the second half of 2020.
The approval of Suvexx by Health Canada supports our growth strategy of building our commercial presence in Canada with new and innovative medicines. Suvexx was one of the assets acquired during the acquisition of the Aralez Canada business and we are pleased to be able to bring Suvexx to market so quickly after closing that transaction, said Jesse Ledger, Nuvo's President & Chief Executive Officer. We will leverage our existing relationships with neurologists and physicians who treat migraineurs across Canada to support and grow the Suvexx brand. These relationships were established from our 7 years of growing Cambia. Our Canadian commercial team has already initiated pre-commercial launch activities.
Migraine patients suffer with a diminished quality of life and reduced productivity surrounding migraine attacks. Suvexx helps patients manage acute migraine attacks using a combination of sumatriptan succinate and naproxen sodium in a single tablet.
The clinical development of Suvexx was extensive and included a total of 13 phase 3 studies, treating thousands of patients, to examine acute migraine, menstrual migraine and patients intolerant of other currently approved migraine medications. Suvexx demonstrated early and sustained efficacy superior to sumatriptan and naproxen alone with a safety and tolerability profile similar to sumatriptan and naproxen. We see Suvexx as an excellent addition to the health care professionals tool kit to help manage their patients' migraines, said Dr Bernard Chiasson, Nuvo's Chief Scientific Officer.
✔️ Nuvo Pharmaceuticals Announces Health Canada Approves Suvexx For The Acute Treatment of Migraine
💕 Found this article helpful? Spread the word and support us!